NECA Health Technology Assessment: When Korea Requires HTA Before Reimbursement
NECA HTA evaluates new medical technologies for safety and effectiveness before HIRA listing. Here's when HTA is required and how to navigate it.
What Is NECA HTA
NECA HTA serves as a gatekeeper for novel technologies entering Korean reimbursement. If HTA is required and the technology fails review, HIRA reimbursement listing is unlikely.
When NECA HTA Is Required
NECA HTA typically required when:
Trigger 1: Novel Technology
Device or procedure represents new technology not covered by existing HIRA codes:
- New therapeutic approach
- New diagnostic modality
- Significantly different from existing covered technologies
Trigger 2: New Reimbursement Category
When HIRA listing request involves new category creation:
- No existing category fits
- New code required
- New reimbursement framework
Trigger 3: High-Cost Devices
Devices with cost significantly above existing covered alternatives:
- Cost-effectiveness justification required
- Health economic value demonstration
- Comparative effectiveness analysis
Trigger 4: AI/ML and Digital Health
Novel AI/ML or digital health technologies often require NECA HTA:
- Clinical effectiveness uncertainty
- Korean validation needed
- Long-term outcomes evidence required
Trigger 5: Government or Provider Request
HIRA, MFDS, or Ministry of Health may request NECA HTA for specific technologies.
When NECA HTA Is Avoidable
NECA HTA typically not required when:
- Device equivalent to existing HIRA-listed devices
- Reimbursement at parity with existing codes
- Established technology with extensive Korean clinical use
- Minor improvements to existing approved technologies
Strategic implication: Many manufacturers can structure HIRA submission to avoid NECA HTA, reducing timeline by 6–12 months.
NECA HTA Process
Phase 1: HTA Application (Months 1–2)
Application includes:
- Device description and intended use
- Existing clinical evidence
- Proposed Korean clinical evidence plan
- Health economics analysis
- Comparator selection rationale
Phase 2: Scoping (Months 2–4)
NECA scoping:
- Research questions defined
- Comparators confirmed
- Outcome measures selected
- Korean clinical relevance assessed
Phase 3: Systematic Review (Months 4–8)
NECA conducts:
- Systematic literature review
- Clinical effectiveness analysis
- Safety profile assessment
- Korean patient population relevance
Phase 4: Economic Evaluation (Months 6–10, may overlap)
NECA evaluates:
- Cost-effectiveness analysis
- Budget impact analysis
- Comparison with existing therapies
- Korean health system perspective
Phase 5: HTA Report and Decision (Months 10–12)
Outcomes:
- Recommended for reimbursement (proceed to HIRA)
- Recommended with conditions (additional evidence, restricted population)
- Not recommended (HIRA pathway difficult)
Korean Clinical Evidence Requirements
NECA HTA typically requires Korean clinical evidence:
| Evidence Type | NECA Acceptance |
|---|---|
| Foreign pivotal clinical trial data | Accepted as supportive |
| Korean clinical study | Strongly preferred |
| Korean real-world evidence | Highly valued |
| Korean registry data | Valued |
| Korean clinical guideline references | Required |
Practical implication: Korean clinical study during MFDS submission strengthens NECA HTA later.
Health Economics Analysis
NECA expects rigorous health economics analysis:
Required Analyses
- Cost-effectiveness analysis (cost per QALY or equivalent)
- Budget impact analysis (5-year horizon typical)
- Sensitivity analysis (key parameters)
- Korean health system perspective
Acceptable Models
- Decision tree analysis
- Markov models
- Discrete event simulation
- Microsimulation
Korean-Specific Considerations
- Korean reimbursement schedules
- Korean treatment patterns
- Korean clinical guidelines
- Korean patient demographics
NECA HTA vs HIRA Review
Different but complementary:
| Aspect | NECA HTA | HIRA Review |
|---|---|---|
| Purpose | Establish clinical and economic value | Determine reimbursement coverage |
| Scope | Comprehensive evidence review | Category and pricing decision |
| Duration | 10–14 months | 9–14 months |
| Cost | $50K–$200K | $30K–$80K |
| Output | HTA report and recommendation | Reimbursement decision and code |
| Sequence | Often before HIRA | After NECA (if required) |
NECA HTA Strategy Options
Strategy 1: Avoid HTA Through Category Alignment
- Align device with existing HIRA category
- Pricing at parity with existing codes
- No NECA HTA required
- Fastest path (HIRA only)
Best for: Devices with strong existing category fit.
Strategy 2: Embrace HTA for Premium Positioning
- Acknowledge NECA HTA as necessary
- Invest in strong health economics evidence
- Pursue premium reimbursement
- Longer path but higher reimbursement
Best for: Devices with clear clinical advantage justifying premium.
Strategy 3: Negotiate Conditional Listing
- Initial HIRA listing at parity to avoid HTA
- Generate Korean real-world evidence
- Future HTA for premium adjustment
Best for: Devices with limited initial Korean evidence but strong potential.
Cost Implications
Without NECA HTA
| Component | Cost |
|---|---|
| HIRA submission | $30K–$80K |
| Korean clinical evidence | $20K–$60K |
| Total | $50K–$140K |
| Timeline | 9–14 months |
With NECA HTA
| Component | Cost |
|---|---|
| NECA HTA submission | $50K–$150K |
| Health economics analysis | $40K–$100K |
| Korean clinical study (if needed) | $100K–$500K |
| HIRA submission (post-HTA) | $30K–$80K |
| Total | $220K–$830K |
| Timeline | 18–30 months |
Common NECA HTA Mistakes
Mistake 1: Insufficient Korean Evidence
International evidence alone often insufficient. Korean clinical context expected.
Fix: Korean clinical study or registry data during MFDS phase.
Mistake 2: Weak Health Economics Model
Generic global health economics model not adapted to Korean health system.
Fix: Korean health economics expert involvement.
Mistake 3: Inappropriate Comparator Selection
Comparator that doesn't reflect Korean clinical practice.
Fix: Korean clinical KOL guidance on appropriate comparator.
Mistake 4: Underestimating Timeline
Planning 12 months total; actual 18–24 months.
Fix: Realistic timeline planning with NECA expertise.
Mistake 5: Sequential vs Parallel Strategy
NECA HTA completed before any reimbursement strategy. Lost time.
Fix: Start HIRA strategy planning in parallel with NECA submission.
Frequently Asked Questions
Q: How do I know if my device requires NECA HTA?
A: Pre-consultation with HIRA helps clarify. Generally: novel technology, new category, premium pricing, or AI/ML devices likely require HTA. Established categories typically don't.
Q: Can we appeal NECA HTA negative decision?
A: Yes, formal appeal process exists. Additional evidence submission common. Approximately 30% of appeals succeed.
Q: Does Leanabl help with NECA HTA?
A: Yes, through health economics partner network. Leanabl's Korea Reimbursement service coordinates NECA HTA and HIRA submission.
Q: What if our device is approved by NECA but not HIRA?
A: Rare scenario. NECA recommendation typically strong indicator of HIRA outcome. If gap occurs, additional evidence or negotiation needed.
Q: How much Korean clinical evidence is "enough"?
A: Depends on device complexity. Typical: 100+ Korean patients across multiple sites for novel devices. NECA scoping clarifies specific expectations.
How Leanabl Helps
- Korea Reimbursement — NECA HTA and HIRA strategy
- HIRA Reimbursement Submission — HIRA execution
- Korea Full Market Authorization — coordinated MFDS + KGMP + HIRA
Contact Leanabl for NECA/HIRA strategy.
Last updated: 2026-05-15.
Have a regulatory question?
Talk to a Korea regulatory specialist about your device, your timeline, or your next submission.
Talk to a specialist
